🇺🇸 FDA
Pipeline program

Tirofiban hydrochloride sodium chloride injection

KY2021-089-08

Approved small_molecule completed

Quick answer

Tirofiban hydrochloride sodium chloride injection for Branch Atheromatous Disease is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Branch Atheromatous Disease
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials